<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01546454</url>
  </required_header>
  <id_info>
    <org_study_id>IRB8023</org_study_id>
    <nct_id>NCT01546454</nct_id>
  </id_info>
  <brief_title>Relationship Between the Menstrual Cycle and Heart Disease in Women</brief_title>
  <official_title>Identification of the Menstrual Cycle-Associated Factors That Modulate Circulating Lipid Levels in Premenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Foundation, Oregon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women who have regular menstrual cycles have a lower risk of heart disease than men of the
      same age or women who no longer have menstrual cycles. The purpose of this study is to help
      determine why the menstrual cycle causes a lower risk of heart disease. The investigators
      believe that the hormones (estradiol and progesterone) produced during the menstrual cycle,
      as well as the normal processes occurring in the follicle and corpus luteum (transformed
      follicle), change levels of &quot;good&quot; and &quot;bad&quot; cholesterol in the blood-stream. These levels of
      good and bad cholesterol are an important risk factor for heart disease. Therefore, our goal
      is to determine what effects each of these factors (estradiol, progesterone, follicle, corpus
      luteum) have on the levels of good and bad cholesterol in the woman's bloodstream. As many
      women take birth control pills, which contain synthetic forms of estradiol and progesterone
      that block ovulation and development of a corpus luteum, the investigators also want to
      determine what effect one common type of birth control pill has on levels of good and bad
      cholesterol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Premenopausal women are at a lower age-adjusted risk of coronary heart disease (CHD) than men
      or postmenopausal women. This decreased risk of CHD is likely due, in part, to the more
      favorable lipid profile observed in premenopausal women. The menstrual cycle is associated
      with the ovarian processes of follicular growth and ovulation, and corpus luteum (CL)
      development, function, and regression. The steroids estrogen (E2) and progesterone (P4) are
      secreted from the follicle and CL, which travel via the bloodstream to elicit their effects
      on target tissues. The production of E2 has been implicated as the menstrual cycle-associated
      factor underlying the favorable lipid profile as it is known to increase atheroprotective
      high density lipoprotein and decrease atherogenic low density lipoprotein. However, other
      factors may play a role such as direct ovarian metabolism of circulating lipids. Furthermore,
      the role of P4 is unclear and there is some evidence that it may inhibit the beneficial
      effects of E2. Therefore, we aim to determine the contributions of ovarian metabolism of
      lipids, independent of the effects of ovarian-derived E2 and P4, to the circulating lipid
      profile in premenopausal women. Also, we will determine the relationship between E2 and P4,
      both natural and synthetic forms found in hormonal oral contraceptives, on circulating
      lipids. With the recent controversial findings of the Women's Health Initiative, further
      evaluation of the factors underlying menstrual cycle protection from CHD is warranted. This
      study may have implications for the management of CHD and the use of hormonal therapies in
      women.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total to HDL Cholesterol Ratio</measure>
    <time_frame>Entire Study</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Non-steroidal effects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Natural menstrual cycle versus Estrogen/Progesterone replacement cycle. Interventions include leuprolide acetate to induce hypogonadism and estradiol and progesterone to replace hormone levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Contraceptive effects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral contraceptive cycle versus Eligard treatment. Interventions include ethinyl estradiol-levonorgestrel combination and leuprolide acetate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroid effects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Estrogen/Progesterone replacement cycle versus Eligard treatment. Interventions include leuprolide acetate, estradiol, and progesterone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethinyl Estradiol-Levonorgestrel combination</intervention_name>
    <description>0.03 mg ethinyl estradiol, 0.15 mg levonorgestrel oral daily for 21 days</description>
    <arm_group_label>Contraceptive effects</arm_group_label>
    <other_name>Portia 21</other_name>
    <other_name>Portia 28</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leuprolide acetate</intervention_name>
    <description>single 22.5 mg subcutaneous depot suspension</description>
    <arm_group_label>Non-steroidal effects</arm_group_label>
    <arm_group_label>Contraceptive effects</arm_group_label>
    <arm_group_label>Steroid effects</arm_group_label>
    <other_name>Eligard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <description>0.05 to 0.3 mg transdermal daily for 26 days</description>
    <arm_group_label>Non-steroidal effects</arm_group_label>
    <arm_group_label>Steroid effects</arm_group_label>
    <other_name>Vivelle-Dot</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>50 to 100 mg vaginal suppositories twice daily for 13 days</description>
    <arm_group_label>Non-steroidal effects</arm_group_label>
    <arm_group_label>Steroid effects</arm_group_label>
    <other_name>First-Progesterone VGS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal menstrual cycles of 25-35 days in length for at least previous 3 cycles

          -  21-40 years of age

          -  BMI &gt; 18, &lt; 30

          -  Serum P4 &gt; 9 ng/ml on single sample collected between days 18-25 of self-reported
             menstrual cycle

          -  Flexible schedule allowing morning blood draws on less than 48 hour notice

          -  In good general health

          -  Commit to remain on stable diet during study period (no changes to normal dietary
             habits)

          -  Commit to using non-hormonal contraceptive methods during study period except those
             prescribed in the experimental protocol

          -  No objections to taking study drugs

        Exclusion Criteria:

          -  Oral contraceptive use or other hormone supplement within the preceding 2 months

          -  Long-acting hormonal contraceptive use in the past 12 months (e.g., Depo-ProveraÂ®)

          -  Contraindications to study drugs

          -  Current or past pregnancy within the previous 6 months or currently trying to conceive

          -  Desiring to conceive in the next 8 months

          -  Breastfeeding in the past 2 months

          -  Diagnosed Diabetes or Metabolic Syndrome

          -  Current or previous use of cholesterol lowering drugs within the preceding 12 months

          -  Diagnosed Polycystic Ovary Syndrome

          -  History of, or self-reported, substance abuse

          -  Smoker

          -  Previous infertility treatment excluding male factor issues

          -  Use of an investigational drug within the past 2 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey T Jensen, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Sciences University, Department of Obstetrics and Gynecology, Women's Health Research Unit</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2012</study_first_submitted>
  <study_first_submitted_qc>March 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <results_first_submitted>April 11, 2014</results_first_submitted>
  <results_first_submitted_qc>October 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 23, 2014</results_first_posted>
  <last_update_submitted>February 17, 2017</last_update_submitted>
  <last_update_submitted_qc>February 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Jeffrey Jensen</investigator_full_name>
    <investigator_title>Director, Women's Health Research Unit</investigator_title>
  </responsible_party>
  <keyword>Premenopausal women</keyword>
  <keyword>coronary heart disease</keyword>
  <keyword>menstrual cycle</keyword>
  <keyword>lipids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One enrolled participant was lost to follow-up prior to receiving any interventions.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Natural Menstrual Cycle</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Oral Contraceptive Cycle</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Eligard Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Estrogen/Progesterone Replacement Cycle</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Healthy premenopausal women from the Portland, OR metro area</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total to HDL Cholesterol Ratio</title>
        <time_frame>Entire Study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-steroidal Effects</title>
            <description>Natural menstrual cycle versus Estrogen/Progesterone replacement cycle. Interventions include leuprolide acetate to induce hypogonadism and estradiol and progesterone to replace hormone levels.
leuprolide acetate: single 22.5 mg subcutaneous depot suspension
Estradiol: 0.05 to 0.3 mg transdermal daily for 26 days
Progesterone: 50 to 100 mg vaginal suppositories twice daily for 13 days</description>
          </group>
          <group group_id="O2">
            <title>Contraceptive Effects</title>
            <description>Oral contraceptive cycle versus Eligard treatment. Interventions include ethinyl estradiol-levonorgestrel combination and leuprolide acetate.
Ethinyl Estradiol-Levonorgestrel combination: 0.03 mg ethinyl estradiol, 0.15 mg levonorgestrel oral daily for 21 days
leuprolide acetate: single 22.5 mg subcutaneous depot suspension</description>
          </group>
          <group group_id="O3">
            <title>Steroid Effects</title>
            <description>Estrogen/Progesterone replacement cycle versus Eligard treatment. Interventions include leuprolide acetate, estradiol, and progesterone.
leuprolide acetate: single 22.5 mg subcutaneous depot suspension
Estradiol: 0.05 to 0.3 mg transdermal daily for 26 days
Progesterone: 50 to 100 mg vaginal suppositories twice daily for 13 days</description>
          </group>
        </group_list>
        <measure>
          <title>Total to HDL Cholesterol Ratio</title>
          <units>Total to HDL Cholesterol Ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.146" lower_limit="0.033" upper_limit="0.26"/>
                    <measurement group_id="O2" value="0.148" lower_limit="-0.13" upper_limit="0.43"/>
                    <measurement group_id="O3" value="-0.89" lower_limit="-2.09" upper_limit="0.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Study Participants</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Randy Bogan</name_or_title>
      <organization>University of Arizona</organization>
      <phone>520-621-1487</phone>
      <email>boganr@email.arizona.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

